147 related articles for article (PubMed ID: 23307545)
1. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
Marik PE; Rivera R
Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
3. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
Human T; Onuoha A; Diringer M; Dhar R
J Crit Care; 2012 Dec; 27(6):745.e1-5. PubMed ID: 22520494
[TBL] [Abstract][Full Text] [Related]
4. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
6. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
8. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
9. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
10. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
[TBL] [Abstract][Full Text] [Related]
12. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Annane D; Decaux G; Smith N;
Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
[TBL] [Abstract][Full Text] [Related]
15. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF; Rock AD; Woodward EJ
Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
[TBL] [Abstract][Full Text] [Related]
16. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
Sughrue ME; McDermott M; Blevins LS
J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
[TBL] [Abstract][Full Text] [Related]
17. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease.
O'Leary JG; Davis GL
Liver Transpl; 2009 Oct; 15(10):1325-9. PubMed ID: 19790137
[TBL] [Abstract][Full Text] [Related]
18. Intravenous conivaptan.
Moen MD; Keating GM
Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
[TBL] [Abstract][Full Text] [Related]
19. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
20. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]